Hepatocellular Carcinoma Market

1
Hepatocellular Carcinoma (HCC) Market
Insights, Epidemiology and Market Forecast-2027
2
Hepatocellular Carcinoma (HCC)
Hepatocellular carcinoma (HCC) is the most common
type of liver cancer, and, also a leading cause
of cancer-related death worldwide.
01
02
03
04
The disease is found to be more common in males
as compared to females.

• DelveInsight 2018 All rights reserved

3
Cases of (HCC)
The total incident cases of HCC in the G8
countries i.e., the United States, EU-5 countries
(Germany, France, Italy, Spain and the U.K.),
Japan and China, were found to be 4,58,170 in
2016, while the corresponding diagnosed advanced
HCC cases in the G8 countries were found to be 1,
60,565 for the same year.

• DelveInsight 2018 All rights reserved

4
Market Outlook
The analysis conducted for the period of
2016-2027, the market size of Hepatocellular
Carcinoma is expected to reach USD 3.8 Billion in
2027 for the G8 countries.
The United States had the highest market share of
HCC in 2016, as compared to the EU5 countries
(Germany, France, Italy, Spain UK) Japan and
China.
Among the EU5 countries, Italy accounted for the
highest market size, while the UK had the lowest
market in 2016.

• DelveInsight 2018 All rights reserved

5
Emerging Therapies
(Companies)
(Drugs)
LENVIMA

• DelveInsight 2018 All rights reserved

6
Report
HCC Report Insights
Hcc Report Key Strengths
Hcc Report Assessment

• DelveInsight 2018 All rights reserved

7
Complete Information
For complete information on
Hepatocellular Carcinoma (HCC) Market Insights,
Epidemiology and Market Forecast-2027 please
click the link below
CLICK HERE
OR
Write Us At 
info_at_delveinsight.com

• DelveInsight 2018 All rights reserved

8
About DelveInsight
1
2
3

• DelveInsight 2018 All rights reserved

9
Service Offerings by DelveInsight

• DelveInsight 2018 All rights reserved

10
Contact Us
info_at_delveinsight.com
91-11-4568 9769
www.delveinsight.com
blog/delveInsight/
twitter/delveInsight
LinkedIn/delveInsight

• DelveInsight 2018 All rights reserved

11
(No Transcript)